Indication
Hindgut Neuroendocrine Tumor
2 clinical trials
2 products
Clinical trial
Prospective Randomized Phase II Trial of Pazopanib (NSC #737754) Versus Placebo in Patients With Progressive Carcinoid TumorsStatus: Active (not recruiting), Estimated PCD: 2019-03-05
Product
PazopanibClinical trial
A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)Status: Recruiting, Estimated PCD: 2025-09-30
Product
Abemaciclib